thalidomide has been researched along with Metabolic Syndrome in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was introduced but was discontinued after 2 months due to side effects." | 1.36 | [Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema]. ( Cardot-Leccia, N; Lacour, JP; Ortonne, JP; Passeron, T; Perrin, C; Sillard, L, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krause, A | 1 |
| Märker-Hermann, E | 1 |
| Sillard, L | 1 |
| Passeron, T | 1 |
| Cardot-Leccia, N | 1 |
| Perrin, C | 1 |
| Lacour, JP | 1 |
| Ortonne, JP | 1 |
1 review available for thalidomide and Metabolic Syndrome
| Article | Year |
|---|---|
[Spondyloarthritis including psoriatic arthritis].
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Certolizumab Pegol; Comorbidity | 2014 |
1 other study available for thalidomide and Metabolic Syndrome
| Article | Year |
|---|---|
[Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema].
Topics: Adrenal Cortex Hormones; Drug Resistance; Female; Humans; Immunoglobulin G; Immunoglobulin lambda-Ch | 2010 |